ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
生物醫藥B類股
483.155
-13.603
-2.74%
手動刷新
漲家數:
7
跌家數:
23
平家數:
3
市盈率:
- -
高:
496.758
開:
496.758
低:
480.328
收:
496.758
成交量:
1.15億
成交額:
26.12億
市值:
3,069.30億
流通市值:
2,732.98億
資料載入中...
總覽
新聞
同源康醫藥-B(02410.HK)獲董事長吳豫生增持63.5萬股H股 涉資約209萬港元
中金财经
·
09/10
啓明醫療-B(02500.HK)擬向杭州盈智勤三號股權投資合夥企業發行新股及可轉換債券 募資不超過5億元
智通财经
·
09/10
德琪醫藥-B(06996.HK)授出1152萬份受限制股份單位
智通财经
·
09/10
2026年國家醫保目錄談判收官:「三除外」落地,醫保商保雙軌並行,雙目錄如何重構創新藥支付邏輯
华夏时报网
·
09/10
恒瑞醫藥(01276.HK)自主研發的 1 類創新藥海曲泊帕乙醇胺片獲批新增兩項適應症
智通财经
·
09/10
信立泰重啓H股IPO,創新藥收入站上半壁江山,仍存單品依賴隱憂
蓝鲸财经
·
09/10
ETF日報(09.10)丨臨床風險事件擾動等多因素疊加,創新藥板塊回落 銀行股温和普漲
智通财经
·
09/10
再鼎醫藥(09688)出現大手買入26.84萬股,成交價$18.7,涉資501.908萬
阿斯达克财经
·
09/10
5年13億房租,卡住了「微創系」中報!淄博富豪常兆華再遇難題,高瓴對賭大限將至
时代财经
·
09/10
創勝集團醫藥-B(06628)股價大幅下跌15.306%,現價港幣$0.83
阿斯达克财经
·
09/10
永泰生物-B(06978)股價顯著波動12.821%,現價港幣$0.37
阿斯达克财经
·
09/10
歐康維視生物-B(01477)股價上升6.244%,現價港幣$5.7
阿斯达克财经
·
09/10
京東健康(06618.HK)發布「AI+醫療器械」戰略升級新成果 接入AI產品數量較今年618翻番
智通财经
·
09/10
透景生命(300642.SZ)控股子公司申報醫療器械註冊獲得受理
智通财经
·
09/10
港股異動 | 創新藥概念股繼續走低 國談收官進入結果等待期 海外臨床失敗擾動短期風偏
智通财经
·
09/10
東北證券:創新藥BD和商業化持續兑現 CXO超預期,傳統板塊築底拐點
智通财经
·
09/10
同源康醫藥-B(02410)股價顯著下跌11.159%,現價港幣$3.065
阿斯达克财经
·
09/10
先健科技(01302.HK):Lantval主動脈瓣膜置換系統進入醫療器械特別審查程序
阿斯达克财经
·
09/10
歌禮制藥-B盤初漲近5% 公司啓動ASC36口服片美國I期肥胖症研究
新浪港股
·
09/10
港股異動 | 歌禮制藥-B(01672.HK)早盤漲近5% 公司啓動ASC36口服片美國I期肥胖症研究
智通财经
·
09/10
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BK1574/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":483.15506,"timestamp":1789114133774,"preClose":496.75812,"halted":0,"volume":115323363,"delay":0,"changeRate":-0.027384,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-13.603058,"latestTime":"09-11 16:00:00","open":496.75812,"high":496.75812,"low":480.32812,"amount":2611810568,"amplitude":0.033074,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":3.606253,"peRate":160.422718,"turnoverRate":0.004215,"increases":6,"decrements":25,"flats":1,"marketCap":306930068880,"floatMarketCap":273297591592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":496.75812,"amplitude":0.033074,"preClose":496.75812,"low":480.32812,"pbRate":"3.606253","latestPrice":483.15506,"volume":115323363,"delay":0,"open":496.75812,"prevYearClose":556.26263,"prevWeekClose":532.025,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":532.025,"twentyDayClose":518.327,"sixtyDayClose":434.471,"secType":"PLATE","market":"HK","turnoverRate":0.004215,"peRate":160.422718,"marketCap":306930068880,"floatMarketCap":273297591592,"timestamp":1789114133774,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":7,"down":23,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666594669","title":"同源康醫藥-B(02410.HK)獲董事長吳豫生增持63.5萬股H股 涉資約209萬港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666594669","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666594669?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 22:47","pubTimestamp":1789051624,"startTime":"0","endTime":"0","summary":"格隆汇9月10日丨同源康医药-B(02410.HK)公告,公司董事长、执行董事兼总裁吴豫生已告知公司,于2026年9月8日至2026年9月10日期间,其于公开市场购入63.5万股公司H股(占公司已发行股本总额约0.17%),总代价约为209万港元。吴豫生已告知公司,其未来可能继续根据市场情况购买公司股份。目前预计其将在此基础上进一步购买股份的总金额不超过300万港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260910/32366677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1515","BK1161","09939","02410","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666967845","title":"啓明醫療-B(02500.HK)擬向杭州盈智勤三號股權投資合夥企業發行新股及可轉換債券 募資不超過5億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666967845","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666967845?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 21:20","pubTimestamp":1789046454,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02500","BK1100","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666938635","title":"德琪醫藥-B(06996.HK)授出1152萬份受限制股份單位","url":"https://stock-news.laohu8.com/highlight/detail?id=2666938635","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666938635?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 20:04","pubTimestamp":1789041856,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1583","06996","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666560028","title":"2026年國家醫保目錄談判收官:「三除外」落地,醫保商保雙軌並行,雙目錄如何重構創新藥支付邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2666560028","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666560028?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 19:12","pubTimestamp":1789038763,"startTime":"0","endTime":"0","summary":"9月9日正午,北京西黄城根北街2号全国人大会议中心。最后一家参与商保创新药目录价格协商的企业代表走出大门,历时五天的2026年国家医保目录现场谈判竞价与商保创新药目录价格协商正式收官。新版国家基本医保药品目录与商保创新药目录预计今年11月公布,2027年1月1日起统一执行。五天时间里,124个目录外药品先后完成基本医保谈判竞价,12个创新药冲击商保创新药目录价格协商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609103870706515.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609103870706515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","BK1161","IBBQ","MEDX","BK1574","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666856717","title":"恒瑞醫藥(01276.HK)自主研發的 1 類創新藥海曲泊帕乙醇胺片獲批新增兩項適應症","url":"https://stock-news.laohu8.com/highlight/detail?id=2666856717","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666856717?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 18:48","pubTimestamp":1789037303,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0359202008.SGD","LU1023057109.AUD","BK1161","06978","LU0359201885.HKD","BK1191","01276","BK1574","LU0359201612.USD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666648561","title":"信立泰重啓H股IPO,創新藥收入站上半壁江山,仍存單品依賴隱憂","url":"https://stock-news.laohu8.com/highlight/detail?id=2666648561","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666648561?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 17:29","pubTimestamp":1789032552,"startTime":"0","endTime":"0","summary":"业务层面,信立泰转型取得阶段性成果的同时,核心产品收入集中的风险始终悬而未决。作为转型最重要的产品,信立坦2024 年销售额约 15 亿元,是公司创新药板块最主要的收入来源,公司创新药板块收入高度依赖这一款降压药物。虽然后续信超妥、复立坦、复立安等多款创新产品陆续获批、纳入医保,形成产品梯队,但是这些新产品体量尚小,短期内难以替代信立坦的收入贡献,公司仍然处于单品依赖阶段。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789029785904368871","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4127","159992","FRHC","IBBQ","BK1574","LNGR","BK0028","BK0196","BK1161","BK0188","002294","06978","BK0239","KCE","BK0187","BK0183","REDS","MEDX","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666693435","title":"ETF日報(09.10)丨臨床風險事件擾動等多因素疊加,創新藥板塊回落 銀行股温和普漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2666693435","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666693435?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 16:43","pubTimestamp":1789029788,"startTime":"0","endTime":"0","summary":"临床风险事件扰动等多因素叠加,创新药板块集体回落;定增政策红利释放、中报验证盈利韧性,银行板块温和普涨。行业表现临床风险事件扰动、海外利率预期反复与资金风格轮动三重因素叠加,创新药板块集体回落。截至收盘,恒生创新药ETF华泰柏瑞跌2.93%,报1.356元;港股通创新药ETF工银跌2.67%,报1.132元;港股创新药ETF广发跌2.65%,报1.251元。截至收盘,银行AH优选ETF招商涨1.65%,报1.603元;银行ETF汇添富涨1.56%,报1.5元;银行ETF华夏涨1.39%,报1.829元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LNGR","IBBQ","BK1574","159992","ABEQ","FDN","PRF","ROPE","BKDV","BK4588","VTV","PY","BK4550","EQRR","SPVM","VUSV","06978","VLUE","VMAX","CGVV","VALQ","BK4585","TALV","DFLV","SWP","BK1161","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666653565","title":"再鼎醫藥(09688)出現大手買入26.84萬股,成交價$18.7,涉資501.908萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2666653565","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666653565?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 15:34","pubTimestamp":1789025640,"startTime":"0","endTime":"0","summary":"[大手成交]再鼎医药(09688)在下午03:34出现大手买入,成交量为26.84万,成交价为港币$18.7,涉资501.908万。至目前为止,股价跌6.6%,今日最高价为$19.99,而最低价为$18.63,总成交量为774.13万股,总成交金额港币$1.475亿。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609105363/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609105363/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1588","BK1574","LU2488822045.USD","BK1161","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666653685","title":"5年13億房租,卡住了「微創系」中報!淄博富豪常兆華再遇難題,高瓴對賭大限將至","url":"https://stock-news.laohu8.com/highlight/detail?id=2666653685","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666653685?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 15:27","pubTimestamp":1789025220,"startTime":"0","endTime":"0","summary":"一纸租房合同,直接引发微创医疗(00853.HK)、微创机器人(02252.HK)、心通医疗(02160.HK)、微创脑科学(02172.HK)四家港股上市公司集体停牌,中报延期。上海张江科学城张东路沿线,两座园区比邻而居,北侧为位于张东路1601号的微创集团总部,与之紧邻的南侧,便是引发本次房租争议的位于张东路1661号的物业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609103870530297.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609103870530297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1589","BK1617","BK1258","BK1583","BK1100","02172","BK1229","BK1542","BK1585","00853","688351","02160","BK0251","02252","688277","03913","688016"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666550210","title":"創勝集團醫藥-B(06628)股價大幅下跌15.306%,現價港幣$0.83","url":"https://stock-news.laohu8.com/highlight/detail?id=2666550210","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666550210?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 14:10","pubTimestamp":1789020600,"startTime":"0","endTime":"0","summary":"[下跌股]创胜集团医药-B(06628) 股价在下午02:10比前收市价大幅下跌15.306%,现股价为港币$0.83。至目前为止,今日最高价为$0.98,而最低价为$0.83。总成交量为125.3万股,总成交金额为港币$113.524万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609102348/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609102348/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06628","BK1161","09939","BK1574","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666550618","title":"永泰生物-B(06978)股價顯著波動12.821%,現價港幣$0.37","url":"https://stock-news.laohu8.com/highlight/detail?id=2666550618","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666550618?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 13:54","pubTimestamp":1789019640,"startTime":"0","endTime":"0","summary":"[异动股]永泰生物-B(06978) 股价在下午01:54出现显著波动12.821%,现股价为港币$0.37,比前收市价下跌5.128%5.128%。至目前为止,今日最高价为$0.415,而最低价为$0.365。总成交量为11.9万股,总成交金额为港币$4.696万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131623256_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131623256_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAC26091052/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAC26091052/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06978","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666557473","title":"歐康維視生物-B(01477)股價上升6.244%,現價港幣$5.7","url":"https://stock-news.laohu8.com/highlight/detail?id=2666557473","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666557473?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 13:34","pubTimestamp":1789018440,"startTime":"0","endTime":"0","summary":"[上升股]欧康维视生物-B(01477) 股价在下午01:34比前收市价上升6.244%,现股价为港币$5.7。至目前为止,今日最高价为$5.7,而最低价为$5.335。总成交量为35.634万股,总成交金额为港币$196.122万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133718217_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609101507/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609101507/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666557852","title":"京東健康(06618.HK)發布「AI+醫療器械」戰略升級新成果 接入AI產品數量較今年618翻番","url":"https://stock-news.laohu8.com/highlight/detail?id=2666557852","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666557852?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 13:00","pubTimestamp":1789016408,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1589","BK1142","09996","06618","BK1515","BK1583","LU0051755006.USD","LU0456827905.SGD","SGXZ62798434.SGD","BK1247","BK1615","BK1591","SGXZ86797644.SGD","BK1100","BK1571","BK1574","86618"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666755282","title":"透景生命(300642.SZ)控股子公司申報醫療器械註冊獲得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666755282","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666755282?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 11:50","pubTimestamp":1789012238,"startTime":"0","endTime":"0","summary":"智通财经APP讯,透景生命(300642.SZ)发布公告,公司控股子公司上海脉示生物技术有限公司申报的医疗器械注册申请于近日获得了上海市药品监督管理局的受理,产品名称:四项抗癫痫药物浓度测定试剂盒(液相色谱串联质谱法)。该产品用于检测人体血清样本中的丙戊酸、奥卡西平代谢物(10,11-二氢-10-羟基卡马西平)、托吡酯、左乙拉西坦浓度。临床上用于丙戊酸、奥卡西平代谢物(10,11-二氢-10-羟基卡马西平)、托吡酯、左乙拉西坦血药浓度的监测。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","BK1583","LGHT","AGNG","BK0042","LNGR","HART","IEIH","300642","BK1574","GDOC","BK0046","BK1100","MEDX","BK0239","MDEV","RSPH","PTH","159883"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666755104","title":"港股異動 | 創新藥概念股繼續走低 國談收官進入結果等待期 海外臨床失敗擾動短期風偏","url":"https://stock-news.laohu8.com/highlight/detail?id=2666755104","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666755104?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 10:43","pubTimestamp":1789008234,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06978","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666513175","title":"東北證券:創新藥BD和商業化持續兑現 CXO超預期,傳統板塊築底拐點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666513175","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666513175?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 09:55","pubTimestamp":1789005326,"startTime":"0","endTime":"0","summary":"东北证券主要观点如下:创新药板块:海外创新药产业高景气延续,国产药企有望承接红利Pharma依托多元路径实现营收稳健增长,Biotech凭借BD和商业化释放业绩弹性。多家创新药企业2026H1业绩超预期增长,这与CXO板块公司的半年度业绩相印证,进一步确认了板块的中期产业趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","BK1161","IBBQ","BK0183","MEDX","BK0188","WX","BK1574","LNGR","BK0028","BK0276","06978","000686","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666561551","title":"同源康醫藥-B(02410)股價顯著下跌11.159%,現價港幣$3.065","url":"https://stock-news.laohu8.com/highlight/detail?id=2666561551","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666561551?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 09:50","pubTimestamp":1789005000,"startTime":"0","endTime":"0","summary":"[下跌股]同源康医药-B(02410) 股价在上午09:49比前收市价显著下跌11.159%,现股价为港币$3.065。至目前为止,今日最高价为$3.55,而最低价为$3.065。总成交量为101.4万股,总成交金额为港币$325.457万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126135510179_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126135510179_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609101189/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609101189/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09939","159938","BK1161","02410","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666559799","title":"先健科技(01302.HK):Lantval主動脈瓣膜置換系統進入醫療器械特別審查程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2666559799","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666559799?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 09:41","pubTimestamp":1789004460,"startTime":"0","endTime":"0","summary":"先健科技(01302.HK) 公布,收到国家药品监督管理局通知,确认由附属公司健心医疗与国家心血管病中心中国医学科学院阜外医院联合研发的Lantval主动脉瓣膜置换系统进入医疗器械特别审查程序。该产品适用于主动脉瓣狭窄或狭窄伴关闭不全患者的外科治疗,是全球首款全预装干式瓣膜设计的(免缝合)主动脉瓣膜置换产品,为公司第18个进入国家药品监督管理局该程序的产品。(sl/ad)(港股报价延迟最少十五分钟。沽空资料截至 2026-09-09 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190621110727571_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190621110727571_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543737/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543737/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1600","159883","BK1583","BK1574","BK1100","09996","01302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666597825","title":"歌禮制藥-B盤初漲近5% 公司啓動ASC36口服片美國I期肥胖症研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2666597825","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666597825?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 09:40","pubTimestamp":1789004400,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端歌礼制药-B(01672)盘初涨近5%。截至发稿,涨幅回落,微涨0.50%,报10.11港元,成交额181.76万港元。歌礼制药宣布,在近期获得美国食品药品监督管理局(FDA)批准新药临床试验(IND)后,其已启动ASC36口服片(口服胰淀素受体激动剂多肽)用于治疗肥胖症的美国I期研究。歌礼创始人、董事会主席兼首席执行官吴劲梓博士表示,2026年,我们就多肽管线启动了四项I期研究,ASC36口服片是其中第四项也是最新的一项,这是歌礼多肽管线的一项重要里程碑,也进一步验证了我们专有的POTENT口服多肽递送技术。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-10/doc-iniriafa7893825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01672","BK1161","BK1574","BK1515","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666559944","title":"港股異動 | 歌禮制藥-B(01672.HK)早盤漲近5% 公司啓動ASC36口服片美國I期肥胖症研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2666559944","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666559944?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 09:27","pubTimestamp":1789003653,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","01477","BK1515","BK1161","BK1191","01672"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":3,"totalSize":343,"code":"91000000","status":"200"}]}}